Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)
As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely to hinge less on quarterly fundamentals and more on the probability, timing, and conditions of closing. SEC+1 FOLD last traded around $14.18 (near the offer price), reflecting how quickly the market repriced the shares after the announcement. Investors.com Below is the week-ahead playbook: the latest news as of 21.12.2025, what Wall Street is saying, and the specific catalysts that could